Scientists have discovered that semaglutide, the active ingredient in drugs like Ozempic and Wegovy, offers a new benefit for ...

Novo, however, vastly underestimated the appetite for its new weight-loss jab. Mr Doustdar says it planned for demand to be three times that of Saxenda, an older and less-effective weight-loss drug.

At present, around 59 million adults worldwide have diabetes, about 64 million are diagnosed with heart failure, and ...

Whether space, health, technology or environment, here are the issues in science that the editors of Scientific American are ...

I am bullish on healthcare stocks, especially pharmaceuticals, due to conservative valuations. Check out the healthcare ...

Researchers analysed 48 previously-conducted trials which examined the safety and efficacy of GLP-1 drugs on people with type ...

CHRISTMAS… it’s THE ultimate eating challenge. But for the millions of us reportedly on weight loss jabs, what misery awaits?

Obesity is a big driver of healthcare spending in South Africa, yet most medical schemes still limit cover for effective ...

The Indian judiciary did well not to let Novo Nordisk extend its exclusive right to sell semaglutide, marketed as Ozempic and ...

Wegovy® (semaglutide injection) granted conditional marketing authorization for the treatment of non-cirrhotic metabolic dysfunction-associated ...

US Ag Secretaru says bill marks a significant step forward in strengthening school nutrition and supporting America’s dairy ...

Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...